Evommune Stock Earnings Estimates Lifted by HC Wainwright

Evommune, Inc. (NYSE:EVMN – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Evommune in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($3.28) per share for the year, up from their prior forecast of ($3.41). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Evommune’s current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Evommune’s Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.91) EPS and FY2027 earnings at ($3.45) EPS.

Several other research firms also recently issued reports on EVMN. Morgan Stanley initiated coverage on shares of Evommune in a research note on Tuesday, October 20th. They set an “overweight” rating and a $26.00 price target for the company. Leerink Partners reduced their price objective on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 9th. UBS Group started coverage on Evommune in a report on Sunday, October 11th. They issued a “neutral” rating and a $8.00 price objective for the company. Royal Bank Of Canada lowered their target price on Evommune from $29.00 to $21.00 and set an “outperform” rating for the company in a research report on Wednesday, September 9th. Finally, Needham & Company LLC cut their target price on Evommune from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evommune currently has a consensus rating of “Moderate Buy” and an average target price of $30.50.

Read Our Latest Stock Report on Evommune

Evommune Price Performance

EVMN opened at $7.09 on Tuesday. Evommune has a fifty-two week low of $4.94 and a fifty-two week high of $33.20. The company’s 50 day moving average price is $7.45 and its two-hundred day moving average price is $17.04. The firm has a market capitalization of $257.24 million and a price-to-earnings ratio of -1.86.

Evommune (NYSE:EVMN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.03).

Institutional Trading of Evommune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in Evommune during the 1st quarter worth approximately $20,615,000. Stempoint Capital LP lifted its position in shares of Evommune by 184.1% in the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock worth $4,385,000 after purchasing an additional 125,581 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Evommune in the 1st quarter worth approximately $10,308,000. Defilade Capital Management L.P. boosted its stake in shares of Evommune by 215.0% in the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after purchasing an additional 463,171 shares during the last quarter. Finally, Eversept Partners LP bought a new stake in shares of Evommune in the 1st quarter valued at $1,257,000.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Featured Articles

Earnings History and Estimates for Evommune (NYSE:EVMN)

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.